Chronic Lymphocytic Leukemia Clinical Trials Database - Free Access to 270 Studies
Access comprehensive clinical trial information for Chronic Lymphocytic Leukemia through Pure Global AI's free database. This collection includes 270 clinical trials across multiple phases including Phase 2, N/A, Phase 1. Currently, 26 trials are actively recruiting participants.
Research for Chronic Lymphocytic Leukemia is being conducted in United States of America, Germany, Italy and 7+ other countries. Leading sponsors include German CLL Study Group and M.D. Anderson Cancer Center. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.
Exercise as Intervention in Chronic Lymphocytic Leukemia
A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
Acalabrutinib Real World Italian obSErvational Study -ARISE
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia
PICAROS - Acalabrutinib RWE on 1L CLL in Spain
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia Patients
HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia
The frequency of uMRD in Japanese patients with CLL after 24 months of treatment with Venetoclax plus/minus Rituximab in the 2L+ in the real-world setting
Front-Line Venetoclax and Obinutuzumab combination followed by Venetoclax or Venetoclax and Zanubrutinib combination in patients with residual disease: a minimal residual disease (MRD) tailored treatment for young patients with high risk CLL. A phase II multicenter study (VIS trial)
A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom
AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry
Untitled Trial
National Acalabrutinib Observational Study
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
ITGA4 Gene Methylation Status in Chronic Lymphocytic Leukemia
Ibrutinib Adapted to Response in Patients With CLL
Pure Global AI provides free access to 270 clinical trials studying Chronic Lymphocytic Leukemia, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.
The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.
Top research sponsors include German CLL Study Group, M.D. Anderson Cancer Center, Gilead Sciences, among others.